Survival With Patients Treated With Salivary Gland Cancer

May 22, 2022 updated by: Denis Brajković, Clinical Center of Vojvodina

Prognostic Factors for Survival of Patients With Salivary Gland Malignancies

Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996. to 31. December 2021. Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods

Study Type

Observational

Enrollment (Actual)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Serbia
      • Novi Sad, Serbia, 11000
        • Clinic for maxillofacial surgery Clinical center of Vojvodina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients treated due to SGC in the Clinic for maxillofacial surgery at Clinical center of Vojvodina

Description

Inclusion Criteria:

Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery

Exclusion Criteria:

Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients free of the disease
Patients treated due to SGC without local recurrence or metastases
Procedure: Surgical intervention with or without postoperative adjuvant therapy
Surgical intervention with or without postoperative adjuvant therapy
Patients with the disease
Patient with relapse of SGC, metastases or died due to SGC
Procedure: Surgical intervention with or without postoperative adjuvant therapy
Surgical intervention with or without postoperative adjuvant therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients survival
Time Frame: Through study completion, an average of 1 year
Survival of patients treated due to SGC during observation period of minimum 2 years
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Clinical Center of Vojvodina

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Actual)

March 30, 2022

Study Completion (Actual)

April 30, 2022

Study Registration Dates

First Submitted

May 18, 2022

First Submitted That Met QC Criteria

May 22, 2022

First Posted (Actual)

May 25, 2022

Study Record Updates

Last Update Posted (Actual)

May 25, 2022

Last Update Submitted That Met QC Criteria

May 22, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1106012

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe